People
The People
Governance grade: B+. Centene has a competent, professionally managed board with strong independence (7 of 9), no founder/family control, and a CEO with meaningful stock ownership. The main concern: executive compensation is heavily weighted toward adjusted metrics that exclude the very impairments and charges that defined FY2025.
The People Running This Company
Sarah London is a 45-year-old CEO leading a $195B-revenue company through its most turbulent period. She inherited a business mid-integration (WellCare), navigated the founder's death (Neidorff, Nov 2022), took the $6.7B goodwill impairment, and is now executing a multi-segment margin recovery. Her Optum background gives her credibility on data-driven care management. Recent leadership changes (Dan Finke as Group President for Medicaid/Commercial, Michael Carson for Medicare/PDP/Specialty) signal she's building a team for the next phase.
What They Get Paid
CEO pay of $19.5M is reasonable for a Fortune 25 company. The 80% stock-award weighting creates long-term alignment. However, the non-equity incentive is tied to adjusted EPS — the same metric that excluded $7.2B in impairments in FY2025. This creates a structural incentive to classify charges as non-recurring, though the specific FY2025 adjustments were largely non-discretionary.
Are They Aligned?
Skin-in-the-Game Score (1-10)
CEO Shares (K)
CEO Stock Value ($M)
3yr Buybacks ($B)
Ownership is meaningful. CEO London holds 1.19M shares worth ~$64M at current prices, representing roughly 3.3x her annual compensation. CFO Asher holds 748K shares (~$40M). These are significant holdings that create real downside exposure.
Insider activity: no open-market selling. Recent Form 4 filings show only "F" transactions (tax withholding on vesting) and "A" transactions (stock awards). No executive has sold shares on the open market in the recent data. This is a positive signal during a period of stock price weakness.
Capital allocation has been shareholder-friendly. Buybacks totaled $7.9B from FY2022–2024, reducing share count by 15%. No buybacks are in FY2026 guidance, reflecting balance-sheet conservatism during the recovery period. No dividend has ever been paid — reasonable for a company in margin-recovery mode.
Related-party risk: none identified. No material related-party transactions in the proxy or filings.
Skin-in-the-game score: 7/10. Executives have meaningful stock ownership, no open-market selling, and the board has been disciplined on capital allocation. The score is docked for (1) compensation tied to adjusted metrics and (2) the absence of meaningful insider buying during the stock price decline from $80+ to $34.
Board Quality
Board strengths: 7 of 9 independent. Strong financial expertise (Tanji — former Prudential CFO chairing Audit; Blume — former Deloitte Vice Chairman; Coughlin — former Tyco CFO). Median tenure under 5 years reflects significant board refreshment since 2021–2022, post-Neidorff era. Diverse board (5 of 9 self-identified diverse).
Board weaknesses: Frederick Eppinger has served 20 years — an outlier that could impair true independence despite formal classification. Kenneth Burdick is a former CNC executive, which creates a comfort risk even though he's classified as non-independent. Missing expertise: no dedicated healthcare provider/clinician perspective, which is notable for a company spending $158B annually on medical claims.
The Verdict
Governance Grade: B+. Professional management team with meaningful stock ownership, a refreshed and financially skilled board, no related-party concerns, and no insider selling. Deductions for compensation tied to adjusted EPS and the absence of insider buying during the trough.
Strongest positives: CEO and CFO each hold more than $40M in stock. Board was substantially refreshed post-2021. No related-party transactions. Capital allocation discipline (aggressive buybacks at reasonable valuations, halted when balance sheet tightened).
Real concerns: Adjusted EPS as the primary compensation metric incentivizes non-recurring charge classification. No executive has been buying stock on the open market despite the stock trading at decade-lows — a missed opportunity to demonstrate conviction. The leadership team is relatively new (most appointed since 2021), and the margin recovery is their first real test.
What would change the grade: A downgrade to B if another large impairment surfaces or if insider selling begins. An upgrade to A- if executives begin meaningful open-market purchases at current prices.